Small-molecule JAK1 inhibitors such as tofacitinib and baricitinib have been approved for rheumatoid arthritis but lack specificity and pose an increased risk of viral respiratory tract infection [27]. The gene discussed is JAK1; the disease is rheumatoid arthritis.